HUP0302278A2 - Neoplazmák kezelése vírusokkal - Google Patents

Neoplazmák kezelése vírusokkal

Info

Publication number
HUP0302278A2
HUP0302278A2 HU0302278A HUP0302278A HUP0302278A2 HU P0302278 A2 HUP0302278 A2 HU P0302278A2 HU 0302278 A HU0302278 A HU 0302278A HU P0302278 A HUP0302278 A HU P0302278A HU P0302278 A2 HUP0302278 A2 HU P0302278A2
Authority
HU
Hungary
Prior art keywords
viruses
treatment
neoplasms
relates
cells
Prior art date
Application number
HU0302278A
Other languages
English (en)
Inventor
Reid W. Borstel
William S. Groene
Robert M. Lorance
Harvey Rabin
Michael S. Roberts
Original Assignee
Pro-Virus, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro-Virus, Inc. filed Critical Pro-Virus, Inc.
Publication of HUP0302278A2 publication Critical patent/HUP0302278A2/hu
Publication of HUP0302278A3 publication Critical patent/HUP0302278A3/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)

Abstract

A találmány tárgyát olyan vírusok képezik, amelyek képesek olyanneoplasztikus sejtekben replikálódni, és ezáltal ezeknek a sejteknek apusztulását okozni, amelyek károsodottak az interferon (IFN) általközvetített antivirális válaszban, valamint a találmány tárgyát képeziezeknek a vírusoknak a felhasználása neoplasztikus betegségek -beleértve a rákot és a nagy tumorokat - kezelésére. Ebből aszempontból jól használhatók az RNS és DNS vírusok. Ó
HU0302278A 1999-04-15 2000-04-17 Treatment of neoplasms with viruses HUP0302278A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29237699A 1999-04-15 1999-04-15
PCT/US2000/010204 WO2000062735A2 (en) 1999-04-15 2000-04-17 Treatment of neoplasms with viruses

Publications (2)

Publication Number Publication Date
HUP0302278A2 true HUP0302278A2 (hu) 2003-10-28
HUP0302278A3 HUP0302278A3 (en) 2011-01-28

Family

ID=23124408

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302278A HUP0302278A3 (en) 1999-04-15 2000-04-17 Treatment of neoplasms with viruses

Country Status (11)

Country Link
US (1) US8043612B2 (hu)
EP (1) EP1390046A4 (hu)
JP (1) JP2003530301A (hu)
CN (1) CN1477964A (hu)
AU (1) AU4246900A (hu)
CA (1) CA2370187C (hu)
HU (1) HUP0302278A3 (hu)
IL (1) IL145899A0 (hu)
MX (1) MXPA01010393A (hu)
NZ (1) NZ550861A (hu)
WO (1) WO2000062735A2 (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CN1289098C (zh) * 1999-09-17 2006-12-13 威尔斯塔生物公司 溶瘤病毒
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
JP5208343B2 (ja) 2000-06-26 2013-06-12 ウェルスタット バイオロジクス コーポレイション ウイルスを用いる細胞の浄化
DE60238044D1 (de) 2001-03-27 2010-12-02 Univ New York Tumortherapie mit vektoren auf sindbis virus-basis
US6750043B2 (en) 2001-04-19 2004-06-15 Arizona Board Of Regents Viral vectors having reduced virulence
CA2442648C (en) * 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy
CA2352439A1 (en) * 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
US20050220818A1 (en) * 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
AU2003249059A1 (en) 2002-07-24 2004-02-09 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
EP2044948B1 (en) 2002-08-12 2013-10-30 Jennerex Biotherapeutics ULC Vaccinia viruses for use in treating cancer
AU2012261681B2 (en) * 2002-08-12 2014-10-02 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2004216928B2 (en) 2003-03-07 2007-03-08 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
RU2005132618A (ru) * 2003-03-24 2006-02-10 Веллстат Байолоджикс Корпорейшн (Us) Применение вируса ньюкаслской болезни
MXPA05010260A (es) 2003-03-27 2006-03-17 Ottawa Health Research Inst Virus de estomatitis vesicular mutantes y usos de los mismos.
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CN100562570C (zh) 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
US20070036758A1 (en) * 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005014017A1 (ja) * 2003-08-08 2005-02-17 Yuji Shino 癌治療用医薬組成物
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
CA2584815C (en) 2004-11-05 2014-03-25 Wellstat Biologics Corporation Stable and filterable enveloped virus formulations
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
JP5190958B2 (ja) * 2005-07-14 2013-04-24 ウェルスタット バイオロジクス コーポレイション ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2621982C (en) 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
US8512713B2 (en) 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
CN102026645B (zh) 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20110318430A1 (en) * 2008-12-18 2011-12-29 New York University Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
WO2011154476A1 (en) * 2010-06-10 2011-12-15 Intervet International B.V. Anti-tumor composition
CA2818701A1 (en) * 2010-11-22 2012-05-31 Nova Southeastern University Modulating oncolytic vsv and upregulating rae1 and nup98 with statins
JP6121910B2 (ja) 2011-01-04 2017-04-26 シラジェン バイオセラピューティクス インコーポレイテッド 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
EP3250550B1 (en) 2015-01-26 2023-04-05 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
EP3442588A4 (en) 2016-04-14 2020-02-19 Trizell Ltd. VIRAL VECTOR STABILIZATION
US10842835B2 (en) 2016-05-25 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US10786537B2 (en) 2016-08-18 2020-09-29 Cedars-Sinai Medical Center Method of inducing an oncolytic effect on tumor cells using Zika virus
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CA3034983A1 (en) 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
EP3621635A4 (en) 2017-05-10 2021-02-24 Wellstat Immuno Therapeutics, LLC WRAPPED VIRUS RESISTANT TO INACTIVATION OF THE CANCER TREATMENT COMPLEMENT
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
NZ224567A (en) 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
AU3183089A (en) 1988-02-11 1989-09-06 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
DE3806565A1 (de) * 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5198336A (en) * 1989-05-08 1993-03-30 Wisconsin Alumni Research Foundation Bioassay for chemicals which generate prooxidant states
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
AU673827B2 (en) 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
US5274137A (en) * 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
DE69426841T2 (de) 1993-02-16 2001-09-06 Onyx Pharma Inc Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
FR2699082B1 (fr) 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
WO1994025627A1 (en) * 1993-04-30 1994-11-10 Lorence Robert M Methods of treating and detecting cancer using viruses
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
ATE223701T1 (de) 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2206205A1 (en) 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
CA2206179C (en) 1994-11-28 2007-10-23 Genetic Therapy, Inc. Vectors for tissue-specific replication
JPH11500736A (ja) 1995-02-24 1999-01-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子治療ベクターを投与するための方法及び組成物
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5853716A (en) 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
AU1550797A (en) 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
EP0954591A2 (en) * 1996-05-31 1999-11-10 Baxter International Inc. Mini-adenoviral vector
JPH105342A (ja) * 1996-06-27 1998-01-13 A S A Sangyo Kk 経腹膜投薬用カテーテル及び投薬容器セット
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
DE69838340T2 (de) * 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
WO1999045783A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
US6602499B1 (en) 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
KR20060080249A (ko) * 1998-06-12 2006-07-07 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
ES2310382T3 (es) 1999-02-05 2009-01-01 Arch Development Corporation Virus herpes modificado geneticamente para el tratamiento de tumores.
AU2905199A (en) * 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
CA2442648C (en) * 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy

Also Published As

Publication number Publication date
EP1390046A2 (en) 2004-02-25
WO2000062735A2 (en) 2000-10-26
MXPA01010393A (es) 2004-04-02
US20090081161A1 (en) 2009-03-26
HUP0302278A3 (en) 2011-01-28
AU4246900A (en) 2000-11-02
EP1390046A4 (en) 2005-04-20
JP2003530301A (ja) 2003-10-14
IL145899A0 (en) 2002-07-25
WO2000062735A3 (en) 2003-11-27
CA2370187C (en) 2011-08-02
CN1477964A (zh) 2004-02-25
US8043612B2 (en) 2011-10-25
CA2370187A1 (en) 2000-10-26
NZ550861A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
HUP0302278A2 (hu) Neoplazmák kezelése vírusokkal
HUP0003911A2 (hu) Neoplazmák kezelése vírusokkal
CA102001S (en) Bottle
HUP0003384A2 (hu) Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék
ES2105698T3 (es) Oligonucleotidos modificados con 7-deazapurina.
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
CY1110416T1 (el) Δικυκλικα παραγωγα ιμιδαζ-5-υλ-αμινης
NO991701D0 (no) HIV og cancer behandling
DE69723057D1 (de) Nukleosid analogen
ATE334670T1 (de) Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen
DK1537140T3 (da) Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer
CA2380924A1 (en) Compositions for treating viral infections, and methods therefor
DK1392522T3 (da) Indretning med skriveflade
DK1372719T3 (da) Nukleinsyre og tilsvarende protein betegnet 125P5C8, der er anvendelig i behandling og påvisning af cancer
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
DE3673672D1 (de) Gefrierresistenter teig und darin verwendbarer mikroorganismus.
CA99905S (en) Container
CA106591S (en) Portable easel
DE122011100041I1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren.
CA102357S (en) Ball-point pen
CA101967S (en) Pacifier
CA98663S (en) Food processor
Boylen et al. Autecological studies in microbial limnology
CA101872S (en) Pocket stamp
Hargreaves Micro economics

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: WELLSTAT BIOLOGICS CORPORATION, US

Free format text: FORMER OWNER(S): PRO-VIRUS, INC., US

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished